Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study
Clinical trial NCT04657822 · RECRUITING
Trial details
- NCT number
- NCT04657822
- Sponsor
- Novartis Pharmaceuticals
- Status
- RECRUITING
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2021-06-10
- Primary completion
- 2031-06-10
- Enrollment
- 130
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.